Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK To Develop LymphoStat-B With Human Genome Sciences

This article was originally published in The Pink Sheet Daily

Executive Summary

Human monoclonal antibody is in clinical development for the treatment of rheumatoid arthritis and systematic lupus erythematosus. The two firms will share jointly in Phase III and IV development costs, as well as in sales and profits.

You may also be interested in...



Human Genome Sciences Plans to Move LymphoStat-B To Phase III

Firm believes it can proceed with Phase III trials of the lupus agent based on subpopulation findings despite its failure to meet primary endpoints in Phase II.

Human Genome Sciences Plans to Move LymphoStat-B To Phase III

Firm believes it can proceed with Phase III trials of the lupus agent based on subpopulation findings despite its failure to meet primary endpoints in Phase II.

GSK, Human Genome Sciences To Co-Develop Antibody For Cancer Treatment

Human Genome Sciences has completed a Phase II trial of HGS-ETR1 for non-small cell lung cancer, with trials ongoing for non-Hodgkin's lymphoma and colorectal cancer.

Related Content

Topics

UsernamePublicRestriction

Register

OM014142

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel